Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial. - Wikidata - wikimedia - TriplyDB

Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.

Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.

http://www.wikidata.org/entity/Q37094993

about

Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.

http://www.wikidata.org/entity/Q37094993

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Intravenous pamidronate versus ...... n-inferiority Phase III trial.

@en

Intravenous pamidronate versus ...... n-inferiority Phase III trial.

@nl

type

label

Intravenous pamidronate versus ...... n-inferiority Phase III trial.

@en

Intravenous pamidronate versus ...... n-inferiority Phase III trial.

@nl

prefLabel

Intravenous pamidronate versus ...... n-inferiority Phase III trial.

@en

Intravenous pamidronate versus ...... n-inferiority Phase III trial.

@nl

P1433

Q37094993-A8FF163A-D9E3-4ED7-A04B-8AFFA5A99BF5

P1476

Q37094993-34786107-54E8-4D2B-8602-9821ED485A12

P2093

Q37094993-210D98EF-AE6F-43AE-9DF7-185A891AF97F

Q37094993-39976CB4-6C23-40F7-8566-2025989619DE

Q37094993-3B1D0985-E4F9-489D-B6DA-5179024668BD

Q37094993-71F8CB99-0E0F-47CC-8019-C939ADE01CD4

Q37094993-96A2529A-A501-4F8C-9A1C-972AF30B50F4

Q37094993-9E6E584E-AED7-4FC6-9740-4A949560765E

Q37094993-B160DFDE-EB50-4F54-990F-5245CBB4BC44

Q37094993-C7C33B02-1576-465B-A423-DE2C95F74FF5

Q37094993-C969EE63-E55D-4675-8C67-A0A763237737

Q37094993-CE5C6815-1383-4C08-BB4A-3A54C54E84C4

P2860

Q37094993-2A69C97F-D3D1-4955-AD29-8981B5405F82

Q37094993-2F917B37-B076-4EA8-B14D-5522A372BEE2

Q37094993-50167E54-7AB7-4FDB-ACFC-39E81F6C8244

Q37094993-61B913CF-EF6A-428D-95FC-6F180340A51D

Q37094993-62112B68-D3CA-4295-BEB9-D32848D4B8DB

Q37094993-66143F2E-0C61-4A93-8B72-5F6E9EE15B82

Q37094993-8A58E9D7-F2FC-46E5-88FF-2BCC704C0448

Q37094993-A1062083-AE26-4952-B64D-B4938500541C

Q37094993-BBDF3AC1-4899-4197-8023-1FD034F00258

Q37094993-BF66091B-6613-430C-8E47-B317BD836825

P304

Q37094993-833CF273-8BFD-4B30-A279-2335727AA05C

P31

Q37094993-6C3E0A37-0C0E-4D68-B777-F252C91F752A

P356

Q37094993-9A531CF2-3180-450F-9DD2-A79EC7E5E38A

P407

Q37094993-0304A5ED-C200-438E-8B2C-C0D6BC37FD61

P478

Q37094993-4525570A-CF0C-4585-99D0-DE1DDD88FF1C

P50

Q37094993-2433B281-6CB0-4281-8A51-9735B5D31E4F

Q37094993-B99EF8BC-A221-4CF9-89D8-57EC16767781

P577

Q37094993-73F2671F-6D68-4051-A53D-765F26063A21

P698

Q37094993-E47D980E-FFFC-4A13-AE0C-AD2049DF27E6

P921

Q37094993-DB610537-51B4-4A1B-8064-FCDD216EA61A

P932

Q37094993-0A03DC92-7F30-447C-89B8-23D4333A25C8

P356

P1433

OncoTargets and Therapy

P1476

Intravenous pamidronate versus ...... n-inferiority Phase III trial.

@en

P2093

Alexandra von Au

http://www.w3.org/2001/XMLSchema#string

Andre Hennigs

http://www.w3.org/2001/XMLSchema#string

Christof Sohn

http://www.w3.org/2001/XMLSchema#string

Christoph Domschke

http://www.w3.org/2001/XMLSchema#string

Eva Milloth

http://www.w3.org/2001/XMLSchema#string

Florian Schuetz

http://www.w3.org/2001/XMLSchema#string

Ingo Diel

http://www.w3.org/2001/XMLSchema#string

Joachim Rom

http://www.w3.org/2001/XMLSchema#string

Joerg Heil

http://www.w3.org/2001/XMLSchema#string

Markus Wallwiener

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonates and other bone agents for breast cancer

Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.

Side effects of bone-targeted therapies in advanced breast cancer.

Bisphosphonates in Breast Cancer Patients with Bone Metastases

Treatment of Bone Metastases in Patients with Advanced Breast Cancer.

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.

Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche.

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

Skeletal complications of malignancy.

P304

4173-4180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S103130

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Schneeweiss

Markus Wallwiener

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27468239

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4944913

http://www.w3.org/2001/XMLSchema#string